DOCSLIB.ORG

Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges. However, propelled crises, including HIV, Ebola, and most recently by our people, products, and purpose, we look Coronavirus—known as COVID-19. forward to the future with great confidence CHAIRMAN’S LETTER • I and optimism as we remain committed to Performance & Purpose leading across the spectrum of healthcare. Over the many decades, we have successfully remained focused on investing in our business Our Credo, Company & Culture to drive growth that generates long-term value, You’ve heard me talk about Our Credo in while also returning value to shareholders almost every communication that I’ve ever and all other stakeholders. In fact, I’m delivered—and this letter is no different. proud to highlight that 2019 marked: Our Credo is the moral compass that we use to guide our business decisions, and it’s the • 36 consecutive years of adjusted blueprint that outlines how we operate and operational earnings growth,* care for the world. Our Credo is the “red • 57 consecutive years of increased thread” that connects our rich heritage, thriving dividends, and workplace culture, and the corporate DNA that • Our continued ranking among Top 10 continues to shape our present and future. Market Cap companies. This “red thread” was quite prominent last Employing our proven capital allocation September. In recognition of the words in strategy enables us to balance our short-term Our Credo standing the test of time, we goals with our long-term aspirations, while celebrated the 75th anniversary of our Initial ensuring we have the resources to invest in Public Offering (IPO) by ringing the historic long-term growth and meet the needs of our Opening Bell at the New York Stock Exchange stakeholders. This is how we live into Our Credo (NYSE). Although we had been in business for values and apply equal focus and commitment almost 60 years, General Robert Wood Johnson II to both our performance and purpose. Our drafted Our Credo shortly before he took four key capital allocation priorities include: the Company public in 1944, creating an opportunity for people to invest in our vision • Investing in growth opportunities for our of healthcare and to also understand how business that deliver health solutions to the we would fulfill that vision. This bold move world, via the research and development of forward sharpened the focus of Johnson new ideas and new approaches. Our substantial & Johnson and helped us forever open our investment in innovation spanned multiple aperture and create a global approach for opportunities, including our continued work defining the future of healthcare every day. with CAR-T (chimeric antigen receptor T-cell therapy) to treat multiple myeloma and bring new hope to patients fighting this devastating disease. We are also investing in novel ways to Our Credo is the “red thread” that connects eliminate disease at its earliest stage through our rich heritage, thriving workplace the World Without Disease Accelerator culture, and the corporate DNA that (WWDA) efforts. The WWDA is currently exploring several innovative approaches that continues to shape our present and future. focus on using digital twins to monitor, maintain and personalize an individual’s health. Today I’m proud to see that we have shareholders • Delivering a competitive dividend to our from every walk of life, small retail investors to shareholders, which increased for the 57th large institutions, as well as current employees consecutive year, paying out nearly $10 billion to retirees. Diverse as they are, the one thing to shareholders in 2019. our shareholders hold in common is the belief in our Company, our values, our people, our • Pursuing mergers, acquisitions and licensing performance and our purpose. Their trust agreements that we believe will add significant and confidence inspire us to continue the long-term value for our shareholders and all pursuit of exceeding their expectations and other stakeholders. Mergers and acquisitions creating long-term shareholder returns. have accounted for approximately 40% of our II • CHAIRMAN’S LETTER operational growth over the past five years. In competition and generic erosion, as well as new total, throughout 2019 we completed 13 major competitive entrants and price reductions. acquisitions and noteworthy licenses, and 100 innovation deals. We also made 19 new Our robust growth can again be attributed equity investments from Johnson & Johnson to volume and is a reflection of the increased Innovation - JJDC, Inc. number of patients we are reaching with our • Considering other prudent ways to return transformational medicines for unmet needs. value to shareholders, such as through share repurchase programs. We initiated a $5 billion share repurchase in December Leading across the Pharmaceutical, of 2018, which was completed in the third Medical Devices and Consumer sectors quarter of 2019. provides us with a unique and powerful Today, there is an increased emphasis on perspective that enables us to see more, corporate purpose. However, across Johnson touch more, learn more and do more & Johnson, we have always operated under the belief that there is a tightly linked connection across the full spectrum of health, as between our Company’s purpose—to advance well as throughout every stage of our health for humanity, and our performance— patients’ and consumers’ lives. to create and deliver shareholder value. Delivering life-saving and life-changing Leading Across the Spectrum of Healthcare medicines to people around the globe We are the most broadly-based global company in translated into Johnson & Johnson having the the healthcare industry. We consider this scope a third-largest Pharmaceuticals business in the strategic business advantage, and we also assume world, retaining our #1 leadership position in the responsibility that comes with it. Leading the United States, and being ranked #1 in the across the Pharmaceutical, Medical Devices and Pharmaceuticals category on Fortune’s annual Consumer sectors provides us with a unique and “World’s Most Admired Companies” list. powerful perspective that enables us to see more, touch more, learn more and do more across the Our Pharmaceutical investments in research full spectrum of health, as well as throughout and development continued to fuel exceptional every stage of our patients’ and consumers’ lives. growth as well. We achieved double-digit growth for 10 key products and delivered We have established a sustainable business strong performance across all regions, in model that is built for the long-term and both developed and emerging markets. provides us with increased confidence about We’re very proud and excited that: our strategic direction and the future of the healthcare industry. We remain focused on • We gained approval and launched two new driving the next generation of innovation across transformational medicines: SPRAVATO for our entire portfolio—in new markets, in existing treatment-resistant depression and BALVERSA markets where we have greater opportunity to for metastatic urothelial cancer. compete, and in the markets where we lead, • We also continued to maximize the value of which include our 26 platforms that each deliver our in-market brands for patients, submitting a billion dollars or more in sales annually. numerous filings and receiving approvals for new line extensions for key brands, including Pharmaceuticals STELARA, DARZALEX, IMBRUVICA, TREMFYA In Pharmaceuticals, our strong track record and ERLEADA, many with peak sales potential of success continued again in 2019, as our that is greater than $500 million. Pharmaceutical segment outpaced the market, growing
Load more

Recommended publications
  • From the Academy
    FROM THE ACADEMY Joint American Academy of DermatologyeNational Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy Craig A. Elmets, MD (Co-Chair),a HenryW.Lim,MD,b Benjamin Stoff, MD, MA,c Cody Connor, MD,a Kelly M. Cordoro, MD,d Mark Lebwohl, MD,e AprilW.Armstrong,MD,MPH,f Dawn M. R. Davis, MD,g Boni E. Elewski, MD,a Joel M. Gelfand, MD, MSCE,h Kenneth B. Gordon, MD,i AliceB.Gottlieb,MD,PhD,j Daniel H. Kaplan, MD, PhD,k Arthur Kavanaugh, MD,l Matthew Kiselica, BA/BS,m Dario Kivelevitch, MD,n Neil J. Korman, MD, PhD,o Daniela Kroshinsky, MD, MPH,p Craig L. Leonardi, MD,q Jason Lichten, MD,m NehalN.Mehta,MD,MSCE,r Amy S. Paller, MD,s Sylvia L. Parra, MD,t Arun L. Pathy, MD,u Elizabeth A. Farley Prater, MD,v Reena N. Rupani, MD,e Michael Siegel, PhD,m BruceE.Strober,MD,PhD,w,x Emily B. Wong, MD,y Jashin J. Wu, MD,z Vidhya Hariharan, PhD,aa and Alan Menter, MD (Co-Chair)n Birmingham, Alabama; Detroit, Michigan; Atlanta, Georgia; San Francisco, Los Angeles, San Diego, and Irvine, California; New York, New York; Rochester, Minnesota; Philadelphia and Pittsburgh, Pennsylva- nia; Milwaukee, Wisconsin; Portland, Oregon; Dallas and San Antonio, Texas; Cleveland, Ohio; Boston, Massachusetts; St. Louis, Missouri; Bethesda, Maryland; Chicago and Rosemont, Illinois; Sumter, South Carolina; Centennial, Colorado; Oklahoma City, Oklahoma; Farmington, Connecticut; and Waterloo, Ontario, Canada Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world’s population.
    [Show full text]
  • Abbvie Allergan Acquisition
    Creating a New Diversified Biopharmaceutical Company The Combination of AbbVie and Allergan Investor Presentation June 25, 2019 NO OFFER OR SOLICITATION This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this presentation is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued in the acquisition are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. The acquisition will be made solely by means of the Scheme Document (or, if applicable, the Takeover Offer document), which will contain the full terms and conditions of the acquisition, including details with respect to the AbbVie shareholder vote in respect of the acquisition. Any decision in respect of, or other response to, the acquisition, should be made only on the basis of the information contained in the Scheme Document. IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with the proposed Acquisition, Allergan will file with the Securities Exchange Commission (the “SEC”) a Proxy Statement, which will include the Scheme Document.
    [Show full text]
  • 2019 Health for Humanity Report
    2019 Health for Humanity Report Progress in Sustainability Report Summary Contents Message from Our Chairman and CEO 3 Sustainability Approach 4 2019 Year in Brief 5 Better Health for All: Tackling the World’s 6 Toughest Health Challenges Better Health for All: Access, Community 7 Health & Innovation Responsible Business Practices 8 Environmental Health 9 UNICEF, the Government of Vietnam and Johnson & Johnson are partnering on a national program to train more than 500 ethnic minority midwives in remote regions to provide effective maternal and child health interventions including early essential newborn care in village clinics and homes. Photo by Paul Bettings Front cover Volunteers, frontline health workers and government officials at the launch of the Umurinzi vaccination program in Rwanda. In October 2019, Johnson & Johnson committed to donating up to 700,000 regimens of Janssen’s investigational Ebola vaccine to support the Ebola outbreak response in Rwanda and the Democratic Republic of the Congo. Photos by Rwanda Ministry of Health 2019 Health2017 for Health Humanity for HumanityReport Summary Report 33 Message from Our Chairman and CEO Dear Johnson & Johnson Stakeholders, We know this mission will always be unfinished, and affirmed unequivocally that there is a fundamental that we will occasionally fall short. But that only serves connection between serving all stakeholders and 2019 was a year of profound change and great contrasts as motivation to move faster than we’ve ever moved generating sustainable, long-term value. around the globe. before in making bigger strides toward some of our most ambitious goals. And as we’ve detailed in this Report, we The demands for global healthcare and responsible We saw unprecedented innovation and encouraging have plenty of positive momentum worth recognizing.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Johnson & Johnson
    JOHNSON & JOHNSON FORM 10-K (Annual Report) Filed 02/22/13 for the Period Ending 12/30/12 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/12 http://www.edgar-online.com © Copyright 2013, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2012 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Annual Report on Annual Reports 2016
    ANNUAL REPORT ON ANNUAL REPORTS 2016 TOP 400 ANNUAL REPORTS WHO RANKS WHERE? 100 ANNUALS IN BRIEF BEST REPORTING PRACTICES Company Value > Report Value Annual Report on Annual Reports 2016 Contents Report rating scale 3 Top 400 annual reports 4 Who ranks where? 25 From ABB to ZTE 100 annuals in brief 58 From Abbott to Yamaha How important is the annual report today? 92 Views from Cecilia Ketels, Kellie Friery, Renee Carter, David Robinson, Kaevan Gazdar, Elena Moskvina, Thomas Rosenmayr, Rob Stangroom, Andrey Kozhevnikov, Ana Santamarina, Katie Holcomb, Ananda Jagoda Best practices on key report attibutes 100 Strategy, message, investor information, risks, style, online… How we make it 121 How is your report doing? The report scan 127 The report rating panel 128 Robert Berick, Susan Blesener, Renee Carter, Vero Escarmelle, Helena Fournial, Kaevan Gazdar, Mike Guillaume, Pradip Seth, Eva Wolosiuk Making reports pay off 133 e.com – ReportWatch 135 2 Report rating scale A+ ééééé First-rate A éééé(é) Excellent A- éééé Very good B+ ééé(é) Sound B ééé Average B- éé(é) Uneven C+ éé Common C é(é) Substandard C- é Poor D (é) Uncompetitive 3 Top 400 annual reports AkzoNobel (No. 1) Electrolux (No. 2 ) SCA (No. 3) Volvo (No. 4) 4 Report rank Company Country Report rating Compare 1 AKZONOBEL Netherlands A+ DUPONT 2 ELECTROLUX Sweden A+ WHIRLPOOL 3 SCA Sweden A+ KIMBERLY-CLARK 4 VOLVO Sweden A+ DAIMLER 5 POTASHCORP Canada A+ AGRIUM 6 ATLAS COPCO Sweden A SANDVIK 7 STORA ENSO Finland A UPM 8 BOLIDEN Sweden A GLENCORE 9 WIENERBERGER Austria A BORAL 10
    [Show full text]
  • Faculty Disclosure
    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
    [Show full text]
  • Health Advisory
    Health Advisory July 2, 2021 • Information for Pierce County Healthcare Providers Communicable Disease Control Communicable Disease Control • (253) 649-1412 3629 S. D St. • Tacoma, WA 98418 (253) 649-1412 • (253) 649-1358 (fax) COVID-19 Updates for Providers Requested actions • Be aware Washington State Department of Health (DOH) issued a behavioral health provider alert about Fourth of July celebrations and other summertime gatherings. The alert asks providers to give patients information about safe social behaviors and the potential negative effects of impulsive behaviors following the state’s full reopening and the misperception that the COVID-19 pandemic has ended. • Be aware the U.S. Food and Drug Administration (FDA) updated the following Emergency Use Authorization (EUA) fact sheets to include the possible risk of pericarditis and myocarditis following vaccination: o Pfizer fact sheet for healthcare providers. o Pfizer fact sheet for patients. o Moderna fact sheet for healthcare providers. o Moderna fact sheet for patients. • Continue to report any case of myocarditis and pericarditis among people who received COVID-19 mRNA vaccine within the last 2 weeks. o Promptly report cases to the U.S. Vaccine Adverse Events Reporting System (VAERS). o Report cases to the Health Department’s 24-hour reporting line at (253) 649-1413. Include vaccine manufacturer, vaccine lot number, vaccination date, dose number, patient gender, age and history of prior SARS-CoV-2 infection. • Be aware the FDA extended the shelf life of Janssen (Johnson & Johnson) COVID-19 vaccine from 3 months to 4½ months. Visit Janssen’s lot expiry checker to determine the updated expiration of your vaccine.
    [Show full text]
  • 1 UNITED STATES DISTRICT COURT DISTRICT of MINNESOTA Shirley
    CASE 0:10-cv-01821-JNE-JJK Document 65 Filed 04/05/11 Page 1 of 5 UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA Shirley Venus Shannon, Plaintiff, v. Civil No. 10-1821 (JNE/JJK) ORDER Baxter Healthcare Corporation, Hospira, Inc., and Abbott Laboratories, Inc., Defendants. In April 2010, Shirley Venus Shannon brought this action against Eli Lilly & Company and several unidentified entities. In October 2010, she filed an Amended Complaint against Baxter Healthcare Corporation, Hospira, Inc., and Abbott Laboratories, Inc. Abbott Laboratories and Hospira moved to dismiss the case for improper venue, see Fed. R. Civ. P. 12(b)(3); moved to dismiss the case for failure to state a claim upon which relief can be granted, see Fed. R. Civ. P. 12(b)(6); and moved to transfer the case to the United States District Court for the Northern District of Illinois, Eastern Division, see 28 U.S.C. § 1404(a) (2006). After answering, Baxter Healthcare joined the motions of Abbott Laboratories and Hospira. Baxter Healthcare did not separately submit memoranda of law. Shannon opposed the motions, but she asserted that the case should be transferred to the United States District Court for the Western District of Tennessee, Western Division. For the reasons set forth below, the Court transfers this action to the Western District of Tennessee. The Court first considers whether this case should be dismissed for improper venue. See Fed. R. Civ. P. 12(b)(3). The defendant bears the burden of establishing improper venue. United States v. Orshek, 164 F.2d 741, 742 (8th Cir.
    [Show full text]
  • No. 33981 2 No
    Pretoria, 4 February 2011 Februarle No. 33981 2 No. 33981 GOVERNMENT GAZETTE, 4 FEBRUARY 2011 IMPORTANT NOTICE The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's respon­ sibility to phone and confirm that the documents were received in good order. Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients. CONTENTS INHOUD Bladsy Koerant Page Gazette No. No. No. No. No. No. GENERAL NOTICE ALGEMENEKENNISGEWING Health, Department of Gesondheld, Departement van General Notice A/gemene Kennisgewing 58 Medicines and Related Substances Act 58 Wet op Beheer van Medisyne en (101/1965): Medicines Control Council: Verwante Stowwe (101/1965): Conditions of registration of a medicine Medisynebeheerraad: Voorwaardes vir in terms of the provisions of section die registrasie van 'n medisyne in terme 15 (7) ..................................................... .. 3 33981 van die bepalings van artikel 15 (7) ........ 4 33981 STAATSKOERANT, 4 FEBRUARIE 2011 No. 33981 3 GENERAL NOTICE ALGEMENE KENNISGEWING NOTICE 58 OF 2011 MEDICINES CONTROL COUNCIL CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council 2.
    [Show full text]
  • 1 Azbil Telstar Tecnologies S.L.U
    AZBIL TELSTAR TECHNOLOGIES, S.L.U. 1 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 AUDIT PLAN 2020 AZBIL TELSTAR TECNOLOGIES S.L.U Manufacturer Country Address AARTI INDUSTRIES LTD. India Unit IV - Plot No. E-50, MIDC, Tarapur, Tal-Palghar Dist. Thane, Maharashtra 401506 - India Commercial Hub road,Near APIIC Pump House,Plot No:2, Road No:21,J.N.Pharma City (Ramky),Tadi ACACIA LIFE SCIENCES Pvt. Ltd. (BIOCON) India Village, IDA Paravada,Visakhapatnam, India - 531 021 Unit-III Plot No. 842-843, Village-Karakhadi, Taluk-Padra, District-Panchmahal, Vadodara-391 450, ALEMBIC PHARMACEUTICALS LTD. India Gujarat, INDIA ALEMBIC PHARMACEUTICALS LTD. India Village Panelav, Near Baska. Taluka Halol, District Panchmahal - 389 350 Gujarat - India AMI LIFE SCIENCES PVT. LTD. India Block No 82/B, ECP Road, At & Post : Karakhadi-391 450 Ta: Padra, Dist. Baroda, Gujarat, INDIA. AMINO CHEMICALS (MOEHS) Malta MRA 050X, Industrial Estate. Marsa MRS 3000 Malta. AMINO CHEMICALS (MOEHS) Malta MRA 050X, Industrial Estate. Marsa MRS 3000 Malta. ANUGRAHA CHEMICALS India D-46-50 &C-62 & 63 KSSIDC Indl Estate Doddaballpura, Bangalore 561 203 INDIA Nº D47 to D50, C62 & C 63, KSSIDC Industrial State, Doddaballapur, Bangalore, Karnataka, 561203 ANUGRAHA CHEMICALS India INDIA ARCH UK BIOCIDES UK Wheldon Road, Castelford, West Yorkshire - WF 102JT, England Consultancy Department March_2020 AZBIL TELSTAR TECHNOLOGIES, S.L.U. 2 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 AURO LABORATORIES LIMITED India K-56, M.I.D.C. Tarapur, Boisar, Dist. Thane, Maharashtra – 401 506, INDIA AUROBINDO UNIT IX India Unit IX.
    [Show full text]
  • Alembic Pharmaceuticals Limited
    Placement Document Not for Circulation and Strictly Confidential Serial Number: ___ ALEMBIC PHARMACEUTICALS LIMITED Registered and Corporate Office: Alembic Road, Vadodara 390 003, Gujarat, India Telephone: +91 265 228 0550; Fax: +91 265 228 2506 E-mail: [email protected]; Website: www.alembicpharmacueticals.com; CIN: L24230GJ2010PLC061123 Alembic Pharmaceuticals Limited (our “Company" or the “Issuer”) was originally incorporated on June 16, 2010 as “Alembic Pharma Limited”, a public limited company under the Companies Act, 1956. Thereafter, our Company commenced its business on July 1, 2010, pursuant to a certificate of commencement of business issued to it by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the name of our Company was changed to “Alembic Pharmaceuticals Limited”, pursuant to a fresh certificate of incorporation consequent upon change of name dated March 12, 2011, issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. For details with respect to changes to the name of our Company, see "General Information" on page 179. Our Company is issuing 80,47,210 Equity Shares (as defined below) at a price of ₹932.00 per Equity Share (the “Issue Price”), including a premium of ₹930.00 per Equity Share, aggregating to approximately ₹750.00 crore (the “Issue”). For further details, see “Summary of the Issue” on page 29. THIS ISSUE IS BEING UNDERTAKEN IN RELIANCE UPON CHAPTER VI OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “SEBI REGULATIONS”) AND SECTION 42 OF THE COMPANIES ACT, 2013 AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED (“COMPANIES ACT”) The equity shares of our Company, of face value of ₹ 2 each (the “Equity Shares”) are listed on BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”, and together with BSE, the “Stock Exchanges”).
    [Show full text]